<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (PPCM) is a poorly understood, <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disorder</z:e> in which left ventricular systolic dysfunction and symptoms of <z:hpo ids='HP_0001635'>heart failure</z:hpo> occur between the last month of pregnancy and the first 5 months postpartum </plain></SENT>
<SENT sid="1" pm="."><plain>Recent data suggest that uncontrolled <z:mp ids='MP_0003674'>oxidative stress</z:mp> leads to the activation of the prolactin cleaving enzyme cathepsin D that in turn leads to an increase in a cleaved 16 kDa prolactin </plain></SENT>
<SENT sid="2" pm="."><plain>This cleaved form that has an angiostatic and proapoptotic role appears to drive the disease by adversely impacting the endothelium and cardiomyocyte </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="3181">Bromocriptine</z:chebi> that reduces the prolactin production by <z:chebi fb="0" ids="51065">dopamine agonist</z:chebi> actions may improve outcomes in patients with peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> by eliminating the cleaved form of prolactin despite the activation of the cleaving enzyme </plain></SENT>
<SENT sid="4" pm="."><plain>In limited case reports and proof of concept studies use of <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> in the early stages has been shown to improve outcomes in patients with peripartum <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>However, larger randomized control study is still awaited </plain></SENT>
</text></document>